Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for 2025. Sales in 2024 totaled $68.7 billion, which beat the Zacks Consensus ...

Schinecker said Roche is expecting a hit of around 1.2 billion Swiss francs ($1.32 billion) in biosimilars in line with last year, which he said was "very much digestible." Sales rose 3% last year ...

Sales at Roche rose 3% last year to 60.50 billion Swiss francs ($66.72 billion). Adjusting for currency movements, sales were up 7%, with growth in both its pharmaceuticals and diagnostics ...

Roche is to bolster its cancer pipeline with the $1.7 billion acquisition of Ignyta. The San Diego based biotech firm’s biggest asset is entrectinib, a selective tyrosine kinase inhibitor being ...

[Operator Instructions] One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to roche.com ... impact was CHF1.1 billion, so exactly in ...

Pen and pump technologies offer convenience and precision. Insulin Pen And Pump Market growth was valued at 32.73 Billion USD in 2023. Insulin Pen And Pump Market Industry is expected to grow from ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

NICHE real estate developer Havitas Properties Inc. said it will launch two leisure projects in Batangas and La Union costing some P2.1 billion, as it lays the groundwork for its entry into the ...